Real-world pharmacovigilance analysis of adverse events associated with selective serotonin reuptake inhibitor antidepressants in children and adolescents
Real-world-Pharmakovigilanzanalyse von unerwünschten Ereignissen bei selektiven Serotonin-Wiederaufnahmehemmern bei Kindern und Jugendlichen
Frontiers in Pharmacology · 02.11.2026 · 17
DOI: 10.3389/fphar.2026.2002544 ↗Auf einen Blick
In FAERS-Meldungen zu 6- bis 18-Jährigen wurden für Fluoxetin, Sertralin und Fluvoxamin verschiedene Sicherheits-Signale gefunden. Für Fluoxetin und Sertralin fiel auch Rhabdomyolyse auf.
Fragestellung
Welche unerwünschten Ereignisse sind in FAERS-Meldungen bei Kindern und Jugendlichen unter Fluoxetin, Sertralin oder Fluvoxamin mit SSRI assoziiert?
Methode
Auswertung von FAERS-Meldungen bis zum 2. Quartal 2026; disproportionality analyses mit ROR, PRR, Bayesian confidence propagation neural network und multi-item gamma Poisson shrinker; Zeit bis zum Ereignis mit Weibull-Modellen.
Ergebnisse
Eingeschlossen wurden 2.614 Meldungen: 1.260 zu Fluoxetin, 1.278 zu Sertralin und 76 zu Fluvoxamin. Rhabdomyolyse: 39 Fälle unter Fluoxetin (ROR 4,26; 95 %-KI 2,81–6,45) und 26 unter Sertralin (ROR 2,69; 95 %-KI 1,71–4,24).
Schlussfolgerung der Autor:innen
Die Studie liefert Hinweise, Symptome, Organsysteme und frühe Überwachungsfenster bei der Verschreibung von SSRI im Kindes- und Jugendalter zu priorisieren.
Kernaussagen
- Psychiatrische und nervale Störungen waren die häufigsten Meldungen.
- Rhabdomyolyse-Signal bei Fluoxetin und Sertralin.
- Frühes Auftreten mit median 24 bzw. 30 Tagen.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.11.2026. Verfasst von Wenjun Yuan und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, China. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gansu University of Chinese Medicine.
Themen: Patientensicherheit, Kinderkrankenpflege
Abstract (Originalsprache)
Background
Depressive disorders are common in children and adolescents, with major depression affecting 3.7% of youth and subclinical symptoms affecting over one-fifth. Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine, sertraline, and fluvoxamine, are prescribed for moderate-to-severe pediatric depression. However, real-world safety signals for specific SSRIs remain incompletely characterized because evidence derives mainly from randomized controlled trials with restrictive inclusion criteria, observational studies affected by prescribing bias, and spontaneous reporting systems without reliable exposure denominators.
Methods
We extracted reports from the U.S. Food and Drug Administration Adverse Event Reporting System through the second quarter of 2026 for depressed children and adolescents aged 6–18 years receiving fluoxetine, sertraline, or fluvoxamine. Disproportionality analyses used reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker to detect signals at system organ class and preferred term levels. Weibull models assessed time to onset, and network toxicology approaches explored candidate targets and pathways underlying the shared rhabdomyolysis signal.
Results
A total of 2,614 reports were included: 1,260 for fluoxetine, 1,278 for sertraline, and 76 for fluvoxamine. Psychiatric and nervous system disorders were the most frequently reported system organ classes for all three drugs. Fluoxetine showed prominent signals for serotonin syndrome, neuroleptic malignant syndrome, rhabdomyolysis, blood creatine phosphokinase increase, and acute kidney injury; sertraline showed strong signals for serotonin syndrome, urinary retention, intentional self-injury, rhabdomyolysis, hepatocellular injury, and respiratory failure. Rhabdomyolysis was reported in 39 fluoxetine cases (ROR = 4.26, 95% CI: 2.81–6.45) and 26 sertraline cases (ROR = 2.69, 95% CI: 1.71–4.24). Time-to-onset analyses revealed an early-failure Weibull pattern for both drugs, with median onsets of 24 and 30 days, respectively. Network toxicology analysis identified shared candidate targets including CYP3A4, CYP2D6, SLC6A4, MAOA, DRD1, DRD2, NOS2, and KCNH2, with enrichment in serotonergic synapse, oxidative stress, and hypoxia response pathways.
Conclusion
This study provides evidence to prioritize symptoms, organ systems, and high-risk monitoring windows in pediatric SSRI prescribing. It offers the first systematic report of SSRI-associated rhabdomyolysis in children and adolescents and translates real-world pharmacovigilance signals into guidance for baseline risk assessment, early monitoring, family education, and symptom-driven laboratory testing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, China.
- College of Clinical Medicine, Shaanxi University of Chinese Medicine, Xianyang, China.
Förderung
- Gansu University of Chinese Medicine
Zitieren
APA
Yuan, W., Zhang, F., Sun, K., Guo, X., Yao, J., Wei, X., Shi, Z., & Shang, J. (2026). Real-world pharmacovigilance analysis of adverse events associated with selective serotonin reuptake inhibitor antidepressants in children and adolescents. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2002544
Vancouver
Yuan W, Zhang F, Sun K, Guo X, Yao J, Wei X, et al. Real-world pharmacovigilance analysis of adverse events associated with selective serotonin reuptake inhibitor antidepressants in children and adolescents. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2002544
BibTeX
@article{Yuan2026,
author = {Yuan, Wenjun and Zhang, Fu and Sun, Kexin and Guo, Xiaotong and Yao, Jingxi and Wei, Xing and Shi, Zhenggang and Shang, Jing},
title = {Real-world pharmacovigilance analysis of adverse events associated with selective serotonin reuptake inhibitor antidepressants in children and adolescents},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.2002544}
}
EUVIMED